John Kent Kane

US Patent:

6822532, Nov 23, 2004

Filed:

Jul 29, 2002

Appl. No.:

10/207670

Inventors:

John R. Kane - Natick MA
Richard J. Garabedian - Bedford NH

Assignee:

Sage Laboratories, Inc. - Natick MA

International Classification:

H01P 308

US Classification:

333116, 333115, 333238, 333244, 333246

Abstract:

A suspended stripline device and method for manufacturing thereof. The device includes first and second conductive traces disposed on a dielectric substrate, each of the first and second conductive traces having a first edge and a second edge, and a housing at least partially surrounding the dielectric substrate, wherein the second edge of each of the first and second conductive traces includes at least one outwardly extending protrusion, the size and orientation of which may be selected so as to compensate for unequal even and odd mode propagation velocities through the suspended-stripline device. The device may be packaged by folding solder-coated tabs, provided on the housing, around the dielectric substrate and heating the device such that the solder melts causing the housing to be secured to the substrate.

US Patent:

6969728, Nov 29, 2005

Filed:

May 10, 2001

Appl. No.:

09/852965

Inventors:

Scott F. Sneddon - Salem MA, US
John L. Kane - Maynard MA, US
Bradford H. Hirth - Littleton MA, US
Fred Vinick - Lexington MA, US
Shuang Qiao - San Diego CA, US
Sharon R. Nahill - Belmont MA, US
John M. Williams - Hopkinton MA, US
Hans-Peter Biemann - Cambridge MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C07C233/00
A61K038/05
A61K038/06
A61K038/07
A61P025/28

US Classification:

514400, 514613, 514241, 51425505, 514256, 564152, 564155, 564159, 5483355, 544209, 544295, 544405

Abstract:

The present invention provides compounds which are modulators of TNF-α signaling and methods of use thereof for treating a patient having a TNF-α mediated condition. The compounds can be represented by the following structural formulas:.

US Patent:

7034031, Apr 25, 2006

Filed:

Mar 10, 2004

Appl. No.:

10/797244

Inventors:

Scott F. Sneddon - Salem MA, US
John L. Kane - Maynard MA, US
Bradford H. Hirth - Littleton MA, US
Fred Vinick - Lexington MA, US
Shuang Qiao - San Diego CA, US
Sharon R. Nahill - Belmont MA, US
John M. Williams - Hopkinton MA, US
Hans-Peter Biemann - Cambridge MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C07D 401/14
C07D 403/14
A61K 31/506
A61P 19/02
A61P 25/28

US Classification:

514256, 514272, 544324, 544328

Abstract:

The present invention provides compounds which are modulators of TNF-α signaling and methods of use thereof for treating a patient having a TNF-α mediated condition. The compounds can be represented by the following structural formulas:.

US Patent:

8304447, Nov 6, 2012

Filed:

May 30, 2008

Appl. No.:

12/601871

Inventors:

Craig Siegel - Woburn MA, US
Cecilia M. Bastos - South Grafton MA, US
David J. Harris - Lexington MA, US
Angeles Dios - Waltham MA, US
Edward Lee - Sudbury MA, US
Richard Silva - Needham MA, US
Lisa M. Cuff - Leominster MA, US
Mikaela Levine - Swampscott MA, US
Cassandra A. Celatka - Hull MA, US
Frederic Vinick - Lexington MA, US
Thomas H. Jozefiak - Belmont MA, US
Yibin Xiang - Acton MA, US
John Kane - Maynard MA, US
Junkai Liao - Tewksbury MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 31/40
A61K 31/4025
C07D 207/04
C07D 405/02

US Classification:

514408, 514422, 548400, 548526

Abstract:

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

US Patent:

8309593, Nov 13, 2012

Filed:

Oct 2, 2009

Appl. No.:

13/122135

Inventors:

Craig Siegel - Woburn MA, US
Cecilia M. Bastos - South Grafton MA, US
David J. Harris - Lexington MA, US
Angeles Dios - Waltham MA, US
Edward Lee - Sudbury MA, US
Richard Silva - Needham MA, US
Lisa M. Cuff - Leominster MA, US
Mikaela Levine - Swampscott MA, US
Cassandra A. Celatka - Hull MA, US
Frederic Vinick - Mechanicville NY, US
Yibin Xiang - Acton MA, US
John Kane - Maynard MA, US
Junkai Liao - Tewksbury MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 31/4025
A61K 31/40

US Classification:

514408, 514422

Abstract:

A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

US Patent:

8399512, Mar 19, 2013

Filed:

Nov 24, 2008

Appl. No.:

12/276856

Inventors:

Laura C. Akullian - Belmont MA, US
Russell C. Petter - Stow MA, US
John J. Kane - Queens Village NY, US
Charles E. Hammond - Billerica MA, US
Mao Yin - Needham MA, US
Aleksandr Yurkovetskiy - Littleton MA, US
Cheri A. Stevenson - Haverhill MA, US

Assignee:

Mersana Therapeutics, Inc. - Cambridge MA

International Classification:

A61K 31/335
C07D 303/00

US Classification:

514475, 549332

Abstract:

Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described. Also described are novel fumagillin analogs, methods of making fumagillin analogs, compositions comprising at least one fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a fumagillin analog.

US Patent:

8518999, Aug 27, 2013

Filed:

Dec 1, 2005

Appl. No.:

11/292325

Inventors:

Scott F. Sneddon - Salem MA, US
John L. Kane - Maynard MA, US
Bradford H. Hirth - Littleton MA, US
Fred Vinick - Lexington MA, US
Shuang Qiao - San Diego CA, US
Sharon R. Nahill - Belmont MA, US
John M. Williams - Hopkinton MA, US
Hans-Peter Biemann - Cambridge MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 31/16
A61K 31/4174
A61K 31/436
A61K 31/395
A61K 45/06
A61P 37/06
C07C 233/00
C07D 233/54

US Classification:

514612, 514613, 514333, 5483361, 564152, 564155, 564159

Abstract:

The present invention provides compounds which are modulators of TNF-α signaling and methods of use thereof for treating a patient having a TNF-α mediated condition. The compounds can be represented by the following structural formulas:.

US Patent:

8524214, Sep 3, 2013

Filed:

May 27, 2010

Appl. No.:

12/789047

Inventors:

Aleksandr Yurkovetskiy - Littleton MA, US
Mao Yin - Needham MA, US
Gui Liu - Lexington MA, US
Laura C. Akullian - Belmont MA, US
John J. Kane - Queens Village NY, US
Cheri A. Stevenson - Haverhill MA, US
Charles E. Hammond - Billerica MA, US
Russell C. Petter - Stow MA, US
John H. Van Duzer - Georgetown MA, US
Timothy B. Lowinger - Carlisle MA, US

Assignee:

Mersana Therapeutics, Inc. - Cambridge MA

International Classification:

A61K 31/045
A61K 31/04
A61K 31/13
A61K 31/21
A61K 31/33
A61K 31/695
A61K 31/765

US Classification:

424 783, 525417, 514 63, 514185, 514183, 514188, 514277, 514280, 514283, 514359, 514449, 514451, 514453, 514510, 514579, 514724, 514740

Abstract:

Polyal-Drug conjugates comprising a variable rate-releasing linker are described along with methods of making such conjugates. Uses for such Polyal-Drug conjugates is also described.